Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New end-to-end option from Definiens
September 2016
SHARING OPTIONS:

MUNICH, Germany—Definiens kicked off August with the release of its Clinical Development Offering, which helps pharmaceutical companies improve patient outcomes and reduce pipeline risk to help advance therapies to market more rapidly. This new offering features Clinical Trial Services, Signature Discovery Services and Companion Diagnostic Services, to aid in activities such as assay development, image analysis and biomarker discovery.
 
“The focus of our new Definiens clinical development offering is to support our partners in maximizing their pipeline, to accurately identify patient populations and therefore deliver the right therapy,” said Thomas Heydler, CEO of Definiens. “We are now providing image analysis, data mining and assay development, combined with deep scientific, regulatory and pathology support. It’s truly an end-to-end offering for biopharma.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.